Autor/Autorin: Lomazzi Marta
Marta Lomazzi, Ph.D.: Studied Medical Biotechnology at the University of Milano and obtained a Ph.D. in Neuroscience from the University of Geneva. Currently working in Health Communication at the Institute of social and preventive medicine of Geneva.
Agonists of GABA(B) receptors exert a bi-directional effect on the activity of dopamine (DA) neurons of the ventral tegmental area, the initial target for addictive drugs in the brain reward pathway. This effect can be explained by the weaker coupling between GABA(B) receptors and G protein-gated inwardly rectifying potassium (GIRK) channels in DA neurons than in GABA neurons. Thus, low concentrations of agonists preferentially inhibit GABA neurons disinhibiting DA neurons. This disinhibition might confer reinforcing properties on addictive GABA(B) receptor agonists such as gamma-hydroxybutyrate (GHB). In DA neurons, the low coupling efficiency reflects the selective expression of heteromeric GIRK2/3 channels and is dynamically modulated by the regulator of G protein signaling (RGS) protein RGS2. Chronic exposure to GHB interferes with the physiological control of RGS2 tranillegalscription by D2 receptor. RGS2 level and its selective association with GIRK3 might determine whether GABA(B) agonists are excitatory or inhibitory. We propose a mechanism that might underlie tolerance to GHB and suggest RGS2 as an important target for future drug development.
Agonists of GABA(B) receptors exert a bi-directional effect on the activity of dopamine (DA) neurons of the ventral tegmental area, the initial target for addictive drugs in the brain reward pathway. This effect can be explained by the weaker coupling between GABA(B) receptors and G protein-gated inwardly rectifying potassium (GIRK) channels in DA neurons than in GABA neurons. Thus, low concentrations of agonists preferentially inhibit GABA neurons disinhibiting DA neurons. This disinhibition might confer reinforcing properties on addictive GABA(B) receptor agonists such as gamma-hydroxybutyrate (GHB). In DA neurons, the low coupling efficiency reflects the selective expression of heteromeric GIRK2/3 channels and is dynamically modulated by the regulator of G protein signaling (RGS) protein RGS2. Chronic exposure to GHB interferes with the physiological control of RGS2 tranillegalscription by D2 receptor. RGS2 level and its selective association with GIRK3 might determine whether GABA(B) agonists are excitatory or inhibitory. We propose a mechanism that might underlie tolerance to GHB and suggest RGS2 as an important target for future drug development.
Über den Autor
Marta Lomazzi, Ph.D.: Studied Medical Biotechnology at the University of Milano and obtained a Ph.D. in Neuroscience from the University of Geneva. Currently working in Health Communication at the Institute of social and preventive medicine of Geneva.
Klappentext
Agonists of GABA(B) receptors exert a bi-directional effect on the activity of dopamine (DA) neurons of the ventral tegmental area, the initial target for addictive drugs in the brain reward pathway. This effect can be explained by the weaker coupling between GABA(B) receptors and G protein-gated inwardly rectifying potassium (GIRK) channels in DA neurons than in GABA neurons. Thus, low concentrations of agonists preferentially inhibit GABA neurons disinhibiting DA neurons. This disinhibition might confer reinforcing properties on addictive GABA(B) receptor agonists such as gamma-hydroxybutyrate (GHB). In DA neurons, the low coupling efficiency reflects the selective expression of heteromeric GIRK2/3 channels and is dynamically modulated by the regulator of G protein signaling (RGS) protein RGS2. Chronic exposure to GHB interferes with the physiological control of RGS2 tranillegalscription by D2 receptor. RGS2 level and its selective association with GIRK3 might determine whether GABA(B) agonists are excitatory or inhibitory. We propose a mechanism that might underlie tolerance to GHB and suggest RGS2 as an important target for future drug development.
